Contact: Dan Lamb
+1 440-420-0987

MENTOR, OHIO – September 9, 2021- STERIS has launched the next generation of integrated Vaporized Hydrogen Peroxide (VHP) biodecontamination systems for Customers wanting to achieve up to a 6-log bioburden reduction in GMP pharmaceutical, medical device and research environments. The new VHP 100i and 1000i are designed to be integrated into a facility’s building automation and HVAC systems, and can run a decontamination cycle at programmed intervals or at the push of a button. This allows for easy and frequent decontamination of rooms, isolators, filling lines, RABs, pass through chambers and more.

“The new VHP systems incorporate input received at thousands of VHP customer sites on five continents,” said Andrea Conroy, Vice President, Marketing for Life Science Equipment and Service at STERIS. “They are engineered to streamline the user experience, offering greater configuration flexibility and ease-of-use.” STERIS VHP offers broad spectrum decontamination to help increase productivity and efficiency and reduce this risk of error by replacing manual cleaning and disinfection steps. STERIS VHP is different from fogging systems because it is a dry, small-molecule process compatible with a broad range of surface materials – even sensitive electronic equipment.

The 100i and 1000i are both members of a family VHP products that leverage the technology’s method of decontamination and sterilization of spaces and products for critical applications and controlled environments across the Life Sciences industry. Both systems also now include Vaprox Link for enhanced regulatory compliance.

For more information about this and other STERIS formulated chemistry products, please visit

STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. For more information, visit


This news release may contain statements concerning certain expectations, forecasts, estimates, product performance or other forward-looking information affecting or relating to the Company or its products that are intended to qualify for the protections afforded "forward- looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," “new,” “advanced,” and “best available,” or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in this news release including, without limitation, disruption of production or supplies, changes in product use, pending or future claims, technology advances, and changes in government regulations or the application or interpretation thereof. No assurances can be provided as to any product performance or product safety unless all labeling, instructions for use, MSDS and other product literature are strictly followed. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in this news release include, without limitation, (a) the possibility that market demand will not develop for new technologies, products or application; (b) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent product introductions, affect the production and marketing of existing products, or otherwise affect product performance; or (c)uses not consistent with product instructions. Product descriptions and performances herein are for illustration only and do not modify labeling, warranties or other technical literature.